细胞外DNA 5-羟甲基脱氧胞苷是对急性髓系白血病 MRD 评估极为敏感的。
Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.
发表日期：2023 Aug 24
作者：
Jianming Shao, Shilpan Shah, Siddhartha Ganguly, Youli Zu, Chuan He, Zejuan Li
来源：
Epigenetics & Chromatin
摘要：
可测量的残余疾病（MRD）是急性髓系白血病（AML）中的一个重要生物标志物。然而，许多患者无法通过目前的方法检测到MRD。我们通过对115例AML患者和86例对照组进行分析，开发出了一种高灵敏度的细胞外DNA中的5-羟甲基脱氧胞苷（5hmC）特征。5hmC方法检测到了29例MRD阴性患者中的20例，这些患者在多参数流式细胞术中MRD呈阴性，并检测到了14例分子方法中MRD呈阴性的患者中的11例。5hmC方法检测到的MRD与无复发生存率显著相关。这种新方法可在大多数AML患者中使用，并可能对AML患者的管理产生重要影响。© 2023年，Springer Nature旗下的BioMed Central Ltd.
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML). However, MRD cannot be detected in many patients using current methods. We developed a highly sensitive 5-hydroxymethylcytosine (5hmC) signature in cell-free DNA by analyzing 115 AML patients and 86 controls. The 5hmC method detected MRD in 20 of 29 patients with negative MRD by multiparameter flow cytometry and 11 of 14 patients with negative MRD by molecular methods. MRD detection by the 5hmC method was significantly associated with relapse-free survival. This novel method can be used in most AML patients and may significantly impact AML patient management.© 2023. BioMed Central Ltd., part of Springer Nature.